Vaxcyte Reports Positive Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate
Phase 3positiveVAX-31Positive
AI Analysis
Summary
Vaxcyte announced positive topline data from the OPUS-1 Phase 3 trial demonstrating that VAX-31, its 31-valent pneumococcal conjugate vaccine candidate, met all prespecified primary endpoints across age groups compared to competing vaccines Prevnar 20 and Capvaxive.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
VAX-31 met all prespecified primary endpoints across age groups compared to Prevnar 20 and Capvaxive
Importance:8/10
Sentiment:
0.85
Phase 3Pneumococcal VaccinePositive DataPivotal TrialPrimary Endpoints Met
Related Companies
Read the original article
Published by GlobeNewswire Clinical Studies on October 5, 2026 10:00 AM